-
The latest edition of touchREVIEWS in Oncology & Haematology has launched and features some of the recent key developments in oncological and haematological disease.
— touchONCOLOGY (@touchONCOLOGY) June 1, 2023
Read it here: https://t.co/leI2gs3gs1 -
Treatment with the first-line combination of pembrolizumab and lenvatinib led to durable anti-tumor activity in patients with nonβclear cell renal cell carcinoma. https://t.co/cUYxt3qB5s #ASCO23 #urology #urologist #kidneycancer
— Urology Times (@UrologyTimes) June 18, 2023 -
π₯¬π₯¦π½π ππ π₯π₯π₯π₯π₯π«π« only π€£π€£π€£ what a world https://t.co/5JyITaz7Cc
— Benjamin J. Davies MD (@daviesbj) June 18, 2023 -
Following our 'no'-majority poll π, we can't wait for #TURBTDebate at #BURSTatBAUS! π₯
— BURST Urology (@BURSTurology) June 18, 2023
π¬ "TURBT on a specialist list ONLY?"
π£οΈ @ParamMariappan vs @HelenaBurden
πͺ @marcuskwesi
π June 20
π°οΈ 14:25-14:50
π Hall 11A
Join the clash! πΏ #BAUS23 #UroSoMe https://t.co/L6mQY2WEpc pic.twitter.com/ZMPXspPjVK -
Dive into this great discussion on unique aspects of #ProstateCancer research within the @VeteransHealth system! π₯π©Ί Join Dr. Isla Garraway @UCLAHealth and @dr_coops as they explore diversity, disparities, and future directions on UroToday > https://t.co/Cvw8gAqpoI pic.twitter.com/m4284MZSA1
— UroToday.com (@urotoday) June 16, 2023